Entity

Time filter

Source Type

Luxembourg, Luxembourg

Eurofins is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental and consumer products industries and to governments. Eurofins employs more than 15,000 employees across around 190 sites in 36 countries and has about EUR 1.1 billion annual revenues .The Eurofins Group offers a portfolio of over 100,000 reliable analytical methods for characterising the safety, identity, purity, composition, authenticity and origin of products and biological substances. Through research and development, in-licensing and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical science.Eurofins pursued an aggressive strategy of expansion, buying more than eighty competitors worldwide since it was founded. Notable examples include the acquisition in 2005 of the German company MWG-Biotech and in 2011 of the US company Lancaster Laboratories, the latter for 150  million euros. Wikipedia.


Grant
Agency: Cordis | Branch: FP7 | Program: CP-TP | Phase: KBBE.2013.3.5-01 | Award Amount: 3.85M | Year: 2013

The Decathlon project will bring together a broad range of experts and expertise to jointly work on the development of new or improved methods that are needed in the field of 1) food pathogens, 2) traceability of GMOs and 3) customs issues. The project will develop advanced methods for all three application areas with method characteristics that meet the requirements of the individual areas, as will be laid down in minimal performance parameters (MPPs) for the types of methods as will be developed within the Decathlon project. Decathlon brings together all relevant molecular biological and bioinformatics expertise through the participation of expert European researchers in the respective fields of application. Besides technical experts, also field-related, application-oriented scientists will participate for the three areas of interest, which are fully aware of the user requirements for the methods to be developed, also in the light of current and future European regulations. By combining this awareness with technical expertise, user requirements will be translated into technical and bioinformatics method requirements that will form the starting-point for the molecular biological technical methods (including any related bioinformatics module, where applicable) to be developed. In this way the Decathlon project will develop focused DNA-based (on-site) methods for the identified areas of food pathogens, GMOs and customs issues, and at the same time stimulate the development of DNA methods for similar applications in numerous other fields that require high-quality, focused DNA-based detection and identification methods. Decathlon will provide the roadmap and blueprint for this broader application of all methods and modules developed in Decathlon. Furthermore, Decathlon will have the cooperation platform and network in place that will be extended effectively throughout the duration of the project as a consolidated European network of analytical experts.


Grant
Agency: Cordis | Branch: FP7 | Program: CP-TP | Phase: KBBE.2012.2.4-04 | Award Amount: 12.16M | Year: 2013

Up to 20 million European citizens suffer from food allergy. However management of both food allergy (by patients and health practitioners) and allergens (by industry) is thwarted by lack of evidence to either prevent food allergy developing or protect adequately those who are already allergic. iFAAM will develop evidence-based approaches and tools for MANAGEMENT of ALLERGENS in FOOD and integrate knowledge derived from their application and new knowledge from intervention studies into FOOD ALLERGY MANAGEMENT plans and dietary advice. The resulting holistic strategies will reduce the burden of food allergies in Europe and beyond, whilst enabling the European food industry to compete in the global market place. Our approach will build on e-Health concepts to allow full exploitation of complex data obtained from the work in this proposal and previous and ongoing studies, maximising sharing and linkage of data, by developing an informatics platform Allerg-e-lab. This will enable us to (1) Extend and integrate existing cohorts from observation and intervention studies to provide evidence as to how maternal diet and infant feeding practices (including weaning) modulate the patterns and prevalence of allergies across Europe (2) Establish risk factors for the development of severe reactions to food and identify associated biomarkers (3) Develop a clinically-validated tiered risk assessment and evidence-based risk management approach for food allergens for allergens in the food chain (4) Develop clinically-relevant multi-analyte methods of analysis suited to allergen management across the food chain Stakeholders will be integrated into iFAAM to deliver harmonised integrated approaches, including RISK ASSESSORS AND MANAGERS managing population risk, the FOOD INDUSTRY who manage allergens to ensure consumer safety, HEALTH CARE PRACTITIONERS to provide food allergy management plans and dietary advice and ALLERGIC CONSUMERS to manage individual risk.


Rogers H.A.,Eurofins
Journal of Agricultural and Food Chemistry | Year: 2013

Method validation is a critical prerequisite to performing analytical methods in the laboratory. A given analytical method is validated for a specific matrix or matrices. If the matrix to be tested is not included in the original scope of method validation, a validation must be performed to determine if the method is applicable to that particular matrix. A number of organizations, such as AOAC and ISO, publish peer-reviewed methods for cross-industry matrices, whereas others, such as AOCS and AACC, are focused on specific industry segments (fats/oils and cereal grains). When no validated method is available for the analyte of interest, method development and validation must first be performed to ensure that correct identification and quantification of the analyte are being observed and measured. Development of a new method requires an understanding of the chemistry and properties of the analyte to be tested, as well as the various types of instrumentation currently available. Method development and improvement is a continuous process, as technology advances and new instrumentation and techniques become available. This paper addresses some of the decisions related to method development but will primarily focus on validation as it applies to compositional testing of foods, crops, and commodities, the factors that determine method selection, and how extensive the validation need be. © 2013 American Chemical Society. Source


Thomas F.,Eurofins
Journal of agricultural and food chemistry | Year: 2010

Until now, no analytical method, not even isotopic ones, had been able to differentiate between sugars coming from C4-metabolism plants (cane, maize, etc.) and some crassulacean acid metabolism plants (e.g., pineapple, agave) because in both cases the isotope distributions of the overall carbon-13/carbon-12 and site-specific deuterium/hydrogen isotope ratios are very similar. Following recent advances in the field of quantitative isotopic carbon-13 NMR measurements, a procedure for the analysis of the positional carbon-13/carbon-12 isotope ratios of ethanol derived from the sugars of pineapples and agave using the site-specific natural isotopic fractionation-nuclear magnetic resonance (SNIF-NMR) method is presented. It is shown that reproducible results can be obtained when appropriate analytical conditions are used. When applied to pineapple juice, this new method demonstrates a unique ability to detect cane and maize sugar, which are major potential adulterants, with a detection limit in the order of 15% of the total sugars, which provides an efficient mean of controlling the authenticity of juices made from this specific fruit. When applied to tequila products, this new method demonstrates a unique ability to unambiguously differentiate authentic 100% agave tequila, as well as misto tequila (made from at least 51% agave), from products made from a larger proportion of cane or maize sugar and therefore not complying with the legal definition of tequila. Source


Perry A.,Eurofins | Lambert P.,Aston University
Expert Review of Anti-Infective Therapy | Year: 2011

Propionibacterium acnes is a Gram-positive bacterium that forms part of the normal flora of the skin, oral cavity, large intestine, the conjunctiva and the external ear canal. Although primarily recognized for its role in acne, P. acnes is an opportunistic pathogen, causing a range of postoperative and device-related infections. These include infections of the bones and joints, mouth, eye and brain. Device-related infections include those of joint prostheses, shunts and prosthetic heart valves. P. acnes may play a role in other conditions, including inflammation of the prostate leading to cancer, SAPHO (synovitis, acne, pustulosis, hyperostosis, osteitis) syndrome, sarcoidosis and sciatica. If an active role in these conditions is established there are major implications for diagnosis, treatment and protection. Genome sequencing of the organism has provided an insight into the pathogenic potential and virulence of P. acnes. © 2011 Expert Reviews Ltd. Source

Discover hidden collaborations